Tildrakizumab sustained long-term disease control in psoriasis affecting hard-to-treat body areas, according to a report published by AJMC (the American Journal of Managed Care). The finding addresses one of the most persistent pain points in plaque psoriasis management: patients whose scalp, palms, soles or skin folds respond poorly to first-line therapy and face disproportionate quality-of-life burden as a result.

Why hard-to-treat areas matter

Psoriasis in these regions rarely behaves like plaque disease on the trunk or limbs. Thick keratin on the palms and soles can blunt topical penetration. Hair on the scalp complicates adherence. Intertriginous skin narrows the therapeutic menu because irritancy and steroid atrophy limit options. The consequence is familiar to every clinic: patients who look "mild" on overall body surface area but whose function — walking, gripping, working — is badly impaired.

For this population, a biologic that maintains clearance in difficult anatomical sites over an extended period changes the treatment conversation. It shifts the decision from "can we get this patient clear once" to "can we keep them clear for years without escalating or switching."

What tildrakizumab is

Tildrakizumab is an interleukin-23 inhibitor marketed as Ilumya. The IL-23 class targets the p19 subunit of the cytokine, a mechanism now central to moderate-to-severe plaque psoriasis care alongside IL-17 inhibition. The AJMC report frames the drug's durability in hard-to-treat areas as the headline of the new analysis.

Readers should note what the report does and does not specify. The published summary confirms long-term control in difficult-to-treat regions but does not, in the item carried by Derm Field, break out individual PASI figures, body-area-specific response rates, or the length of the observation window. Clinicians evaluating the claim for formulary or treatment-selection purposes should consult the underlying dataset directly rather than extrapolate.

How the finding fits IL-23 practice patterns

Durability is the currency of modern psoriasis pharmacotherapy. Agents that hold response over multiple years reduce the cycling costs — clinical, economic and human — of switching therapies after secondary failure. For hard-to-treat-area patients specifically, durable control in high-impact sites may matter more to daily function than marginal gains in overall PASI response.

The managed-care framing from AJMC also signals where the conversation is heading. Payers increasingly ask whether a drug's persistence data justify preferential positioning; durable control in refractory anatomical sites is exactly the kind of endpoint that supports such arguments. Manufacturers, in turn, lean on long-term extension analyses to defend that positioning once patents and biosimilar pressure enter the calculus.

What this means for the clinic

For dermatologists, the takeaway is directional rather than practice-redefining. When a patient presents with recalcitrant scalp, palmoplantar or flexural disease, IL-23 inhibition with tildrakizumab now has publicized long-term evidence specifically in those areas, not just in general plaque psoriasis cohorts. That nuance can inform shared decision-making, particularly for patients who have failed topicals, phototherapy or TNF inhibitors.

Prescribers should still weigh the standard considerations: patient comorbidities, prior biolecular class exposure, administration schedule preferences and payer coverage. No therapy class is uniformly superior in hard-to-treat sites, and head-to-head data across mechanisms in these specific regions remain limited.

What comes next

Expect the durability signal to feed into longer-term comparative effectiveness research and into payer reviews of IL-23 agent positioning, as tildrakizumab's manufacturer continues to build the case that sustained control in difficult-to-treat psoriasis areas justifies its place in the treatment sequence.